What this page helps you do
Use this guide to prepare a child-specific hematology file in Ghana, keep current treatment uninterrupted, and plan guardian, visa and post-return arrangements before a long journey.
- Before hospital review
- Ask the child’s hematologist to state the confirmed diagnosis, disease severity, current treatment and response, complications and why HSCT or another specialist opinion is being considered.
- Documents
- Include diagnosis-specific evidence, treatment and transfusion history, recent organ-function and infection results, vaccination records and guardian authorization. Do not arrange HLA testing unless requested.
- Travel with a child
- Ghanaian ordinary-passport holders require a visa. Türkiye lists medical treatment as a distinct purpose, so confirm the child’s and accompanying adult’s application requirements before booking.
- Continuity of care
- Keep the Ghanaian pediatric hematology team involved. Agree who will manage medicines, transfusion needs or acute events during review and who will monitor immune recovery if treatment proceeds.
- Sickle-cell disease or another blood disorder does not by itself establish a need for HSCT; the pediatric transplant team must assess benefits, alternatives and risks.
- Current pediatric HSCT availability in Ghana could not be verified from a sufficiently current official program source. This is an evidence gap and must not be read as confirmation that pediatric HSCT services are absent.
Travel information checked 11 October 2026. Reconfirm requirements before booking.
Pediatric BMT Evaluation in Turkey from Ghana
A parent or legal guardian in Ghana may request a preliminary pediatric specialist review when the child’s treating team is considering HSCT or when the family needs a verified second opinion. Review before travel does not confirm treatment or admission.
Local Pediatric Care in Ghana Remains Essential
Ghana’s Ministry of Health publishes sickle-cell treatment guidance and has documented access to hydroxyurea. A diagnosis such as sickle-cell disease must continue to be managed by the child’s Ghanaian team; an international HSCT opinion is an additional case-specific route, not a replacement for established care.
An international review should complement—not interrupt—the child’s current care in Ghana, especially when treatment or infection management is time-sensitive.
A Blood Disorder Does Not Automatically Mean Transplant
A diagnosis such as leukemia, thalassemia or sickle-cell disease does not by itself mean a child needs transplant. The pediatric hematology team must assess the exact condition, severity, treatment response, alternatives, risks and likely benefit.
Specialists may recommend chemotherapy, transfusion care, medicines, cellular therapy, observation or another approach depending on the case.
Acibadem Altunizade Pediatric Program
Official Acibadem sources connect Altunizade Hospital to adult and pediatric bone marrow transplantation and describe multiple cell-source approaches. It is the published campaign partner, not the only verified program available for comparison.
Potential Donor and HLA Assessment
A sibling, parent or other possible donor is not automatically suitable. HLA matching, donor health, consent, child safeguarding, cell source and any registry or legal requirements need separate specialist review.
Families should not arrange informal donor testing or travel based on assumptions. The transplant center defines the appropriate testing sequence.
Preparing the Child’s Records in Ghana
Organize records around the clinical question and preserve original dates and findings.
- Current pediatric hematology summary and the reason a second opinion is requested
- Hemoglobin electrophoresis or other confirmed diagnosis evidence when sickle-cell disease is relevant
- Bone-marrow, pathology, flow-cytometry, genetic or molecular reports when relevant
- Treatment, hydroxyurea or transfusion history and documented response
- Recent blood counts, infection history and available organ-function results
- Guardian identity, authorization and accompanying-adult details
- Available HLA or family-donor information only when requested
Parent or Legal-Guardian Submission
A parent or legally authorized guardian can submit the MedTransplant Case Review. The form records who is submitting, their relationship to the child and the authorization required for representation.
From Case Review to Pediatric Team Response
MedTransplant structures the available file and coordinates submission. The hospital may request pathology review, updated testing, HLA information or a pediatric consultation before deciding whether evaluation can progress.
Request Comparison with Other Verified Programs
Families may explore other verified pediatric programs or request comparison through MedTransplant. The comparison does not rank hospitals by unsupported claims and cannot guarantee acceptance.
Planning Travel from Ghana with a Child
Travel should normally follow hospital feedback. Consider the child’s stability, guardian documents, who must accompany the child, requested tests, infection precautions, accommodation and expected stay.
Case-Specific Financial Planning
No unverified package price is presented. If review progresses, costs can depend on diagnostics, donor work-up, cell collection, conditioning, admission and the proposed treatment pathway.
Returning to Pediatric Care in Ghana
Before any treatment, agree how the local pediatric hematology team and the transplant center will communicate about medicines, infections, blood counts, immune recovery, vaccination and urgent concerns.
Continue with the Acibadem Pediatric BMT Guide
Review the partner-program pathway, diagnostic boundaries, donor safeguards and parent or guardian submission process.
Explore pediatric BMT evaluation at Acibadem AltunizadeFrequently Asked Questions
Can a parent submit a child’s case from Ghana?
Yes. A parent or legal guardian can identify their relationship and authorization in the MedTransplant Case Review.
Does leukemia always require bone marrow transplant?
No. Treatment depends on the leukemia type, risk features, response and available alternatives. Pediatric specialists decide whether HSCT should be considered.
Does thalassemia or sickle-cell disease always require transplant?
No. Severity, current treatment, complications, donor options, alternatives and individual risks all matter.
Is a sibling automatically a suitable donor?
No. HLA matching, health, consent, safeguarding and the proposed cell source require separate hospital-led assessment.
Can MedTransplant find a donor?
No. MedTransplant does not find, recruit, sell, broker or guarantee donors.
Does submission guarantee the child’s acceptance?
No. Submission guarantees neither diagnosis, hospital acceptance, donor approval, transplantation, timing nor outcome.
Can families compare another pediatric program?
Yes. Acibadem Altunizade is the published partner for this campaign, while families may explore other verified programs or request comparison.
When should the family book travel?
Usually after the hospital reviews the available file and describes the possible next assessment steps.
Sources and verification
- Acibadem Altunizade Hospital
- Acibadem Pediatric Bone Marrow Transplantation Unit
- NCI: Stem cell and bone marrow transplants
- NCI: Childhood acute lymphoblastic leukemia treatment
- NCI: Children with Cancer—A Guide for Parents
- Ghana Ministry of Health: Hydroxyurea for sickle-cell disease
- Ghana Ministry of Health: Standard Treatment Guidelines—haematological disorders
- WHO Ghana country health profile
- Türkiye Ministry of Foreign Affairs: Visa information for foreigners
- Türkiye Ministry of Foreign Affairs: General information about Turkish visas
Pediatric medical responsibility
MedTransplant coordinates parent- or guardian-led case preparation and referral. Pediatric specialists make all diagnostic, treatment, donor and acceptance decisions.
